摘要
核因子κB(NFκB) 是一个促炎的转录因子,它的激活,在乳腺癌中是通常可以观察到的现象。它可以促进一个非激素依赖、侵略性的、高级的和晚期的肿瘤表型。而且,通常使用的癌症化疗和放疗方法都会激活NFκB,导致侵袭性乳腺癌的发展并展现出对化疗、放疗和内分泌疗法的抵抗。抑制NFκB将导致癌症细胞对化疗药物和放疗凋亡的敏感性增强,及恢复激素敏感性,这与乳腺癌患者无病存活率的增加是相关的。在本综述中,我们着重介绍了NFκB在乳腺癌发生发展过程中的作用和验证了NFκB作为潜在的乳腺癌预防和治疗的靶标。我们也讨论了近期的关于NFκB在一些癌症类型中可能具有肿瘤抑制活性的发现。最后,本综述概括了最新的用于癌症治疗和预防的NFκB抑制剂的进展,靶标确定中的挑战,及这些药物从实验室走向临床中的药理的和毒性的评估。
关键词: 乳腺癌,促炎,NFκB,转运因子。
Current Medicinal Chemistry
Title:Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Volume: 22 Issue: 2
Author(s): Wei Wang, Subhasree A. Nag and Ruiwen Zhang
Affiliation:
关键词: 乳腺癌,促炎,NFκB,转运因子。
摘要: The activation of nuclear factor-kappaB (NFκB), a proinflammatory transcription factor, is a commonly observed phenomenon in breast cancer. It facilitates the development of a hormone-independent, invasive, high-grade, and late-stage tumor phenotype. Moreover, the commonly used cancer chemotherapy and radiotherapy approaches activate NFκB, leading to the development of invasive breast cancers that show resistance to chemotherapy, radiotherapy, and endocrine therapy. Inhibition of NFκB results in an increase in the sensitivity of cancer cells to the apoptotic effects of chemotherapeutic agents and radiation and restoring hormone sensitivity, which is correlated with increased disease-free survival in patients with breast cancer. In this review article, we focus on the role of the NFκB signaling pathways in the development and progression of breast cancer and the validity of NFκB as a potential target for breast cancer prevention and therapy. We also discuss the recent findings that NFκB may have tumor suppressing activity in certain cancer types. Finally, this review also covers the state-of-the-art development of NFκB inhibitors for cancer therapy and prevention, the challenges in targeting validation, and pharmacology and toxicology evaluations of these agents from the bench to the bedside.
Export Options
About this article
Cite this article as:
Wei Wang, Subhasree A. Nag and Ruiwen Zhang , Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy, Current Medicinal Chemistry 2015; 22 (2) . https://dx.doi.org/10.2174/0929867321666141106124315
DOI https://dx.doi.org/10.2174/0929867321666141106124315 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Recent Development of Small Molecule Glutaminase Inhibitors
Current Topics in Medicinal Chemistry Preface
Current Radiopharmaceuticals PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery The Role of Foxp3 in Regulatory T Cell Differentiation and Function
Current Immunology Reviews (Discontinued) Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
Current Medicinal Chemistry - Anti-Cancer Agents The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Evaluation of Antitumor Activity and Hepatoprotective Effect of Mitomycin C Solubilized in Chamomile Oil Nanoemulsion
Anti-Cancer Agents in Medicinal Chemistry Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Comparison of Large Proteomic Datasets
Current Proteomics Dual Acting Isatin-heterocyclic Hybrids: Recent Highlights as Promising Pharmacological Agents
Letters in Drug Design & Discovery Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Design, Synthesis and Anti-breast Cancer Activity of Some Novel Substituted Isoxazoles as Anti-breast Cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry